[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Davidson B, Alejandro E, Flørenes VA, Goderstad JM, Risberg B, Kristensen GB, Trope CG, Kohn EC: Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer; 2004 May 15;100(10):2139-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma.
  • The objective of the current study was to evaluate the anatomic site-related and cellular expression of GEP and its association with clinicopathologic parameters and survival in patients with advanced-stage ovarian carcinoma.
  • GEP was found in carcinoma cells in 180 of 189 (95%) tumor biopsy specimens, with stromal and endothelial cell expression in 93 of 180 (52%) and 124 of 185 (67%) specimens, respectively.
  • Lower GEP expression in stromal cells was observed in metastases sampled during or after chemotherapy (P = 0.034).
  • Significantly more frequent GEP expression was observed in tumor cells of both primary (P = 0.002) and metastatic (P < 0.001) tissue specimens compared with malignant effusions.
  • CONCLUSIONS: GEP expression was observed in primary and metastatic epithelial ovarian carcinoma specimens, with down-regulated expression in tumor cells of malignant effusions.
  • The poor outcome associated with stromal GEP expression suggests a prognostic role for this growth factor in ovarian carcinoma.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / secondary. Female. Humans. Immunoenzyme Techniques. Middle Aged. Pleural Effusion, Malignant / metabolism. Pleural Effusion, Malignant / pathology. Prognosis. Stromal Cells / metabolism. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15139056.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GRN protein, human; 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


2. Mendivil A, Schuler KM, Gehrig PA: Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control; 2009 Jan;16(1):46-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Understanding the etiology, presentation, evaluation, and management of selected non-endometrioid endometrial adenocarcinomas of the uterine corpus is needed to define optimal treatment regimens.
  • METHODS: The pathology and treatment of selected non-endometrioid endometrial adenocarcinomas of the uterus are reviewed and summarized.
  • RESULTS: The most common non-endometrioid histology is papillary serous (10%), followed by clear cell (2% to 4%), mucinous (0.6% to 5%), and squamous cell (0.1% to 0.5%).
  • Some non-endometrioid endometrial carcinomas behave more aggressively than the endometrioid cancers such that even women with clinical stage I disease often have extrauterine metastasis at the time of surgical evaluation.
  • Therefore, when technically and medically feasible, comprehensive surgical staging is helpful for women with non-endometrioid endometrial cancer histology.
  • While whole abdominal radiotherapy has a limited role in early-stage uterine papillary serous carcinoma (UPSC) and clear cell carcinoma (CC), there may be a role for postoperative chemotherapy and volume-directed radiotherapy in both early-stage UPSC and CC.
  • In the setting of optimally debulked advanced-stage disease, a combination of radiation and chemotherapy may be indicated.
  • In the setting of recurrent disease or in women with residual disease after surgery, a platinum-based regimen or enrollment in a clinical trial is recommended.
  • CONCLUSIONS: UPSC and CC are managed similarly since sufficient data to separate treatment recommendations are lacking.
  • Because both histologies are associated with a high rate of recurrence, adjuvant therapy is recommended even in women with early-stage disease.
  • The remaining cell types should be treated similar to endometrioid or other low-grade histologies.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Uterine Neoplasms / pathology. Uterine Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Female. Gynecologic Surgical Procedures. Humans. Prognosis. Radiotherapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19078929.001).
  • [ISSN] 1526-2359
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 51
  •  go-up   go-down


3. Eltabbakh GH, Shamonki J, Mount SL: Surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy shows well-differentiated tumors. Gynecol Oncol; 2005 Nov;99(2):309-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy shows well-differentiated tumors.
  • OBJECTIVE: The purpose of our study was to assess the surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy showed well-differentiated (FIGO grade 1) carcinoma.
  • MATERIALS AND METHODS: A retrospective study was conducted including all women treated at the University of Vermont between 1992 and 2004 whose preoperative endometrial biopsy was reviewed by the staff at the Pathology Department and diagnosed as FIGO grade 1 adenocarcinoma and who received peritoneal washings, total abdominal (or laparoscopic) hysterectomy, bilateral salpingo-oophorectomy, and pelvic +/- para-aortic lymphadenectomy as part of their surgery.
  • Postoperatively, 131 (72%) patients received no additional treatment, 47 (25.8%) received radiation therapy, 3 (1.6%) received chemotherapy, and 1 (0.5%) received Megace.
  • CONCLUSIONS: Approximately 30% of women with endometrial carcinoma whose preoperative endometrial biopsy shows grade 1 tumors have grade 2 or 3 in the hysterectomy specimen and 12.6% have advanced surgical stage (stage III and IV) disease.
  • Women with preoperative endometrial biopsy showing grade 1 tumors who undergo surgical staging have excellent survival and acceptable operative morbidity.
  • [MeSH-major] Endometrial Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Biopsy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Cell Differentiation / physiology. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16005945.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Wheeler DT, Bristow RE, Kurman RJ: Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol; 2007 Jul;31(7):988-98
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
  • The treatment of complex atypical hyperplasia (CAH) and well-differentiated endometrioid carcinoma (WDC) by progestin therapy has been shown to be a safe alternative to hysterectomy.
  • Accurate assessment for regressive changes induced by the progestins is critical to successful treatment.
  • However, there are few studies detailing the histopathologic changes associated with progestin therapy.
  • A total of 44 patients with CAH or WDC, treated with oral progestins or a progesterone or levonorgestrel-releasing intrauterine device, were followed by endometrial biopsy and/or curettage at 3 to 6 month intervals for a maximum of 25 months.
  • The pretreatment and posttreatment endometrial samples were evaluated for response to treatment and for the histologic features of gland-to-stroma ratio, architectural abnormalities [back-to-back glands and confluency (cribriform and/or papillary patterns)], glandular cellularity, mitotic activity, cytologic atypia, and cytoplasmic changes.
  • Histologic changes seen in progestin-treated endometria included a decreased gland-to-stroma ratio, decreased glandular cellularity, decreased to absent mitotic activity, loss of cytologic atypia, and a variety of cytoplasmic changes including mucinous, secretory, squamous, and eosinophilic metaplasia.
  • Architectural changes tended to resolve later in the course of treatment.
  • Three instances of disease progression occurred, presumably only after discontinuing progestin treatment.
  • Only persistent architectural abnormalities and/or cytologic atypia in the 7 to 9-month biopsies were predictive of treatment failure, with a trend for cytologic atypia to be the most powerful predictor.
  • These findings indicate that progestin therapy should be continued for no less than 6 months to accurately assess treatment response.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology. Progestins / therapeutic use
  • [MeSH-minor] Adult. Cell Nucleus / drug effects. Disease Progression. Endometrium / drug effects. Endometrium / pathology. Female. Humans. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592264.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Progestins
  •  go-up   go-down


5. Schmidt D: [Endometrial carcinomas and precursor lesions--new aspects]. Pathologe; 2009 Jul;30(4):261-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endometrial carcinomas and precursor lesions--new aspects].
  • [Transliterated title] Endometriale Karzinome und Vorstufen--Neue Aspekte.
  • Endometrial carcinomas can be separated into two groups which are designated as type I and type II carcinomas today.
  • Only type I carcinomas are associated with hyperestrogenism.
  • The group of type I carcinomas consists of endometrioid carcinoma and its variants, and mucinous carcinoma.
  • The prototypes of type II carcinomas are serous and clear cell carcinoma.
  • Not all carcinomas, however, can be assigned to one of the two groups, because there are hybrid tumors and mixed carcinomas, e.g. endometrioid carcinoma with a serous component.
  • The precursor lesions of the endometrioid carcinoma and the serous carcinoma are well characterized morphologically and by molecular pathology.
  • Atypical hyperplasia is the precursor lesion of endometrioid carcinoma, whereas endometrial intraepithelial carcinoma (EIC) is the precursor lesion of serous carcinoma.
  • No precursor lesion has as yet been identified for clear cell carcinoma.
  • Immunohistochemical markers for endometrial carcinoma are CK7 and vimentin, for serous carcinoma markers are p53 and p16.
  • Correct typing is of essential prognostic necessity in endometrial carcinoma.
  • Of utmost importance is the detection of a serous component, because serous carcinoma leads to early tumor spread with the necessity of radical surgery, chemotherapy and radiotherapy.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology
  • [MeSH-minor] Biomarkers / analysis. Carcinoma / pathology. Female. Humans. Hyperplasia. Menopause. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Am J Clin Pathol. 2005 Dec;124 Suppl:S42-51 [16468417.001]
  • [Cites] Pathology. 2007 Feb;39(1):134-8 [17365829.001]
  • [Cites] Adv Anat Pathol. 2002 May;9(3):145-84 [11981113.001]
  • [Cites] Int J Surg Pathol. 2000 Oct;8(4):279-289 [11494005.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):434-40 [9277658.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):403-12 [4005805.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):569-75 [8179072.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):177-85 [9006334.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):287-90 [10684697.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):769-74 [7793474.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Int J Gynecol Cancer. 2004 Mar-Apr;14(2):348-53 [15086736.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jul;26(3):328-33 [17581420.001]
  • [Cites] Pathol Res Pract. 1992 Oct;188(7):856-9 [1448376.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):157-66 [15644772.001]
  • [Cites] Int J Gynecol Pathol. 1998 Apr;17 (2):129-34 [9553809.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1740-7 [8859187.001]
  • [Cites] Pathology. 2007 Feb;39(1):46-54 [17365822.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1561-73 [15785748.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1519-30 [17122507.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):463-9 [14675663.001]
  • [Cites] Mod Pathol. 2009 Jan;22(1):37-42 [19116629.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19495762.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Vimentin
  •  go-up   go-down


6. Akizuki S, Katsumata N, Yamanaka Y, Andoh M, Fujiwara Y, Watanabe T: Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients. Int J Clin Oncol; 2005 Aug;10(4):272-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients.
  • We evaluated the feasibility of weekly paclitaxel in patients with recurrent or advanced endometrial carcinoma who had failed treatment with cyclophosphamide, doxorubicin, and cisplatin (CAP).
  • We treated four patients with CAP-resistant recurrent or advanced endometrial carcinoma with paclitaxel.
  • Paclitaxel (80 mg/m(2); infused over 1 h) was administered weekly for a maximum of 18 weeks, unless disease progression or intractable toxicity developed.
  • Two patients developed grade 3 leukopenia or neutropenia.
  • Outpatient treatment with weekly paclitaxel was well-tolerated and feasible for patients with CAP-resistant recurrent or advanced endometrial carcinoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Endometrioid / drug therapy. Drug Resistance, Neoplasm. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / secondary. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Cyclophosphamide / therapeutic use. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / secondary. Doxorubicin / therapeutic use. Feasibility Studies. Female. Humans. Infusions, Intravenous. Maximum Tolerated Dose. Middle Aged. Salvage Therapy. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2365-9 [11981009.001]
  • [Cites] Semin Oncol. 1996 Dec;23(6 Suppl 16):32-4 [9007118.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):278-81 [8751561.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(3):235-42 [8098996.001]
  • [Cites] Am J Clin Oncol. 1996 Jun;19(3):290-1 [8638543.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3353-61 [9779712.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1021-9 [11181665.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):816-25 [8631019.001]
  • [Cites] Int J Clin Oncol. 2003 Feb;8(1):45-8 [12601542.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):861-3 [8922203.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Aug;29(8):1371-6 [12214463.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2159-66 [15169803.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-78-S15-82 [9346228.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-62-S15-67 [9346225.001]
  • (PMID = 16136374.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; CISCA protocol
  •  go-up   go-down


7. Lee KR, Nucci MR: Ovarian mucinous and mixed epithelial carcinomas of mullerian (endocervical-like) type: a clinicopathologic analysis of four cases of an uncommon variant associated with endometriosis. Int J Gynecol Pathol; 2003 Jan;22(1):42-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian mucinous and mixed epithelial carcinomas of mullerian (endocervical-like) type: a clinicopathologic analysis of four cases of an uncommon variant associated with endometriosis.
  • The epithelial cells of ovarian mucinous carcinomas may sometimes appear similar to those of gastrointestinal or endocervical mucinous carcinomas, but most are composed of cells that do not suggest any particular derivation.
  • We report four cases of mucinous ovarian carcinoma in which the cells were entirely or almost entirely endocervical-like.
  • Two patients had bilateral tumors confined to the ovaries at initial staging; both also had synchronous endometrial carcinomas of the mucinous type.
  • In one of the latter cases a mullerian (endocervical-like) mucinous borderline tumor (MMBT) of the opposite ovary had been removed 5 years earlier, and in this case and two other cases the ovarian carcinomas had foci resembling MMBT, suggesting that they may be an invasive counterpart to these tumors.
  • There was abundant intraglandular and intracystic mucin.
  • The epithelial cells were well differentiated with infrequent mitoses and most were tall with mucinous cytoplasm resembling normal endocervical glandular cells.
  • Endometriosis was present in residual ovarian tissue adjacent to four tumors in three patients and had marked epithelial proliferation in three.
  • All patients were treated postoperatively with chemotherapy and were without clinical recurrence with follow-up intervals of 8 months, 1.2 years, 2.9 years, and 3.8 years.
  • By immunohistochemical analysis the neoplastic epithelium was positive for estrogen and progesterone receptor proteins, vimentin, and cytokeratin 7, and negative or only focally positive for carcinoembryonic antigen and cytokeratin 20, a profile that differs from that of the usual mucinous ovarian carcinoma and is supportive of a mullerian derivation.
  • To better understand their clinicopathologic features and pathogenesis, this uncommon variant should be separated from the usual type in future studies of mucinous carcinomas of the ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Endometriosis / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12496697.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


8. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR: Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother; 2004 Jan;58(1):24-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum tumor markers in the management of ovarian, endometrial and cervical cancer.
  • CA 125 is the most reliable serum marker for ovarian carcinoma.
  • Whereas its role in the screening of the malignancy is controversial, serum CA 125 assay is very useful for both the differential diagnosis of ovarian masses, particularly in postmenopause, and the monitoring of the response to chemotherapy and follow-up of patients with histologically proven ovarian carcinoma.
  • Tumor-associated antigens other than CA 125, such as CA 19.9, CA 15.3 and TAG.72, firstly identified in gastro-intestinal or breast malignancies, have been detected also in tissue and serum samples from patients with ovarian carcinoma.
  • In particular CA19.9 offers the advantage of high sensitivity for mucinous histotype, which often fails to express CA 125.
  • Serum CA 125 correlates with the clinical course of disease better than the other antigens, and in patients with positive CA 125 assay at diagnosis the concomitant evaluation of CA 19.9 or CA 72.4 or CA 15.3 does not offer any additional benefit for monitoring ovarian carcinoma.
  • As for endometrial carcinoma, preoperative serum CA 125 levels correlate with stage, depth of myometrial invasion, histologic grade, cervical invasion, peritoneal cytology, lymph node status and clinical outcome.
  • Moreover, serial CA 125 assay is a good indicator of disease activity and a useful biochemical tool for post-treatment surveillance of patients with endometrial carcinoma.
  • SCC is the most reliable serum marker for squamous cell cervical carcinoma, and in patients with this malignancy pretreatment SCC levels are related to tumor stage, tumor size, depth of cervical invasion, lymph-vascular space involvement, lymph node status and clinical outcome.
  • Serial SCC measurements parallel the response to radiotherapy and chemotherapy as well as the clinical course of disease after the completion of treatment.
  • Serum CYFRA 21.1 seems to be less sensitive than serum SCC for squamous cell cervical carcinoma.
  • [MeSH-major] Biomarkers, Tumor / blood. Endometrial Neoplasms / blood. Endometrial Neoplasms / therapy. Ovarian Neoplasms / blood. Ovarian Neoplasms / therapy. Uterine Cervical Neoplasms / blood. Uterine Cervical Neoplasms / therapy


9. Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD: Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer; 2009 Jul;19(5):860-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
  • To evaluate the potential of epithelial cell adhesion molecule (Ep-CAM/TROP-1)-specific immunotherapy against epithelial ovarian carcinomas (EOCs), we have analyzed the expression of Ep-CAM at RNA and protein level in patients harboring primary, metastatic, and chemotherapy-resistant/recurrent EOC.
  • Epithelial cell adhesion molecule expression was evaluated by real-time polymerase chain reaction and immunohistochemistry in 168 fresh-frozen biopsies and paraffin-embedded tissues.
  • In addition, Ep-CAM surface expression was evaluated by flow cytometry in several freshly established ovarian carcinoma cell lines derived from patients harboring tumors resistant to chemotherapy in vivo as well as in vitro.
  • Epithelial cell adhesion molecule transcript was found significantly overexpressed in primary, metastatic, and recurrent EOC when compared with normal human ovarian surface epithelium cell lines and fresh-frozen normal ovarian tissue (P < 0.001).
  • Similarly, by immunohistochemistry, Ep-CAM protein expression was found significantly higher in primary, metastatic, and recurrent EOC when compared with normal ovarian tissues.
  • Finally, a high surface expression of Ep-CAM was found in 100% (5/5) of the chemotherapy-resistant ovarian carcinoma cell lines studied by flow cytometry.
  • These results demonstrate high Ep-CAM overexpression in ovarian carcinoma, especially in metastatic and recurrent/chemotherapy-resistant ovarian disease.
  • The lack of Ep-CAM expression on the chelomic epithelium in the peritoneal cavity, combined with the recent development of fully human monoclonal antibodies against this surface molecule, suggest Ep-CAM as a promising target for antibody-mediated therapies in ovarian carcinoma patients harboring tumors refractory to standard treatment modalities.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Adhesion Molecules / metabolism. Drug Resistance, Neoplasm. Neoplasm Recurrence, Local / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Blotting, Western. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / secondary. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / secondary. Female. Flow Cytometry. Humans. Immunoenzyme Techniques. Middle Aged. Organoplatinum Compounds / administration & dosage. Ovary / metabolism. Ovary / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574774.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Organoplatinum Compounds; 0 / RNA, Messenger
  •  go-up   go-down


10. Le T, Shahriari P, Hopkins L, Faught W, Fung Kee Fung M: Prognostic significance of tumor necrosis in ovarian cancer patients treated with neoadjuvant chemotherapy and interval surgical debulking. Int J Gynecol Cancer; 2006 May-Jun;16(3):986-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of tumor necrosis in ovarian cancer patients treated with neoadjuvant chemotherapy and interval surgical debulking.
  • The objective of this study was to study the significance of tumor necrosis documented at the time of interval surgical debulking after neoadjuvant chemotherapy.
  • Retrospective chart reviews were carried out from 1997 to 2005 to identify ovarian cancer patients treated with neoadjuvant chemotherapy.
  • Patients' demographics together with disease characteristics, treatment-related variables, and outcomes were recorded.
  • Cox proportional hazard models were built to model time to progression using predictor variables such as age, cancer stage, tumor grade, residual disease, percentage change in CA125 level from baseline, and degree of necrosis in resected tumor specimens.
  • Cox regressions revealed three significant predictive variables of time to first progression: younger age (hazard ratio [HR] = 0.95, 95% CI 0.92-0.98, P= 0.004), residual disease (P= 0.048), and the absence/minimal tumor necrosis after three cycles of neoadjuvant chemotherapy (HR = 1.97, 95% CI 1.01-3.87, P= 0.048).
  • The lack of or minimal tumor necrosis after neoadjuvant chemotherapy is an independent risk factor for recurrent disease.
  • [MeSH-major] Neoadjuvant Therapy. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Aged. Antineoplastic Combined Chemotherapy Protocols. Area Under Curve. CA-125 Antigen / analysis. Carboplatin / therapeutic use. Carcinoma / diagnosis. Combined Modality Therapy. Cystadenocarcinoma, Serous / diagnosis. Disease-Free Survival. Endometrial Neoplasms / diagnosis. Female. Humans. Necrosis. Ovariectomy / statistics & numerical data. Paclitaxel / therapeutic use. Prognosis. Retrospective Studies. Second-Look Surgery / methods. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803473.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


11. Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, Elsasser HP, Nagy A, Schulz KD, Grundker C, Schally AV, Emons G: Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol; 2000 Nov;17(5):1063-9
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines.
  • Eighty percent of human ovarian and endometrial cancers express receptors for luteinizing hormone-releasing hormone (LHRH).
  • These receptors might be used for targeted chemotherapy with cytotoxic LHRH analogs such as AN-152, in which doxorubicin is linked to agonist carrier [D-Lys6]LHRH.
  • The antiproliferative effects of doxorubicin and AN-152 were assessed in LHRH receptor-positive ovarian (EFO-21, EFO-27) and endometrial (HEC-1A, Ishikawa) cancer cell lines as well as in LHRH receptor negative ovarian SKOV-3 and endometrial MFE-296 lines.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents / pharmacology. Doxorubicin / analogs & derivatives. Endometrial Neoplasms / pathology. Gonadotropin-Releasing Hormone / analogs & derivatives. Gonadotropin-Releasing Hormone / antagonists & inhibitors. Neoplasm Proteins / drug effects. Neoplasms, Hormone-Dependent / pathology. Ovarian Neoplasms / pathology. Receptors, LHRH / drug effects
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Biological Transport. Carcinoma, Endometrioid / pathology. Cell Division / drug effects. Cell Nucleus / metabolism. Cystadenocarcinoma, Serous / pathology. Drug Screening Assays, Antitumor. Female. Humans. Microscopy, Confocal. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11029513.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; 0 / Receptors, LHRH; 27844X2J29 / LHRH, lysine(6)-doxorubicin; 33515-09-2 / Gonadotropin-Releasing Hormone; 80168379AG / Doxorubicin
  •  go-up   go-down


12. Papathanasiou K, Tolikas A, Dovas D, Kostopoulou E, Fragkedakis N, Tzafettas J: Simultaneously detected primary malignant tumors of ovary and endometrium with unusual histology. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1191-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of a mucinous adenocarcinoma of the ovary with a synchronous endometroid tumor of the endometrium with focal features of undifferentiated carcinoma and deep myometrial invasion is reported.
  • A review of the literature revealed that our case is interesting in view of the fact that simultaneous presentation of primary ovarian and endometrial neoplasms is rare and usually related to low-stage ovarian lesions and well-differentiated and superficial endometrial carcinomas in contrast to our case with the focal features of undifferentiated carcinoma and the deep myometrial invasion.
  • The prognosis in most of the cases is surprisingly good even after total abdominal hysterectomy and bilateral oophorectomy alone without adjuvant chemotherapy or irradiation.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343211.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Lee KB, Lee JM, Park CY, Lee KB, Cho HY, Ha SY: What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix? A matched case-control study. Int J Gynecol Cancer; 2006 Jul-Aug;16(4):1569-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix? A matched case-control study.
  • The objective of this study was to investigate the efficacy of treatment strategies in patients with adenocarcinoma (AC) of the cervix and compare it with those with squamous cell carcinoma (SCC) of the cervix.
  • Primary radical surgery followed by adjuvant therapy, same as for SCC, would be acceptable for AC with pathologic tumor size of 2-4 cm.
  • Although it was difficult to determine whether AC recurred more systemically, more effective treatment strategies than those currently available for AC should be considered to reduce the systemic recurrence.
  • [MeSH-major] Adenocarcinoma / therapy. Carcinoma, Squamous Cell / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / therapy. Adult. Aged. Antineoplastic Agents / therapeutic use. Case-Control Studies. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / surgery. Endometrial Neoplasms / therapy. Female. Humans. Hysterectomy. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Retrospective Studies. Stromal Cells / pathology. Survival Rate


14. Pulay T, Baki M, Bodoky G, Dank M, Cseh J, Csejtei A, Csömör S, Erfán J, Esik O, Faluhelyi Z, Izsó J, Hernádi Z, Kammerer K, Magyar T, Mayer A, Megyery E, Moskovits K, Pécsi L, Pikó B, Pintér T, Ruzsa A, Szánthó A, Szántó I, Szántó J, Szucs M, Tálos Z, Thurzó L, Kásler M: [The results of ovarian cancer therapy in the Hungarian Centers in 2002-2003]. Orv Hetil; 2006 Dec 31;147(52):2493-500
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The results of ovarian cancer therapy in the Hungarian Centers in 2002-2003].
  • Authors presented data of treatment results and course of disease in 487 ovarian cancer patients treated by primary surgery and paclitaxel-carboplatin combination chemotherapy between July 1, 2002 and December 31, 2003.
  • Distribution of their histological diagnosis was as 69.6% serous, 10.7% mucinous, 5.1% endometrial and 4.7% undifferentiated carcinoma.
  • Most patients started chemotherapy 20 days after surgery and 74.2% of them got six courses.
  • This treatment resulted on a complete remission in 40.9% at the follow-up of 12 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / therapy. Ovarian Neoplasms / therapy. Ovariectomy
  • [MeSH-minor] Adenocarcinoma, Mucinous / therapy. Adult. Aged. Brenner Tumor / therapy. Carboplatin / administration & dosage. Carcinoma, Endometrioid / therapy. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / therapy. Drug Administration Schedule. Female. Humans. Hungary / epidemiology. Middle Aged. Paclitaxel / administration & dosage. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294573.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


15. McCluggage WG, Strand K, Abdulkadir A: Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors. Int J Gynecol Cancer; 2002 Jan-Feb;12(1):62-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metallothioneins (MTs) are a group of low-molecular-weight proteins that are overexpressed in a variety of human neoplasms and are related to differentiation and prognosis in some tumor types.
  • This study investigated immunohistochemically detectable metallothionein expression in benign and malignant ovarian surface epithelial tumors of serous, mucinous, and endometrioid types.
  • Of the malignant tumors, MT expression was found in 68% of endometrioid, 56% of mucinous, and 52% of serous neoplasms.
  • Analogous to the situation in endometrial carcinomas, there is a tendency toward higher expression in poorly differentiated tumors.
  • Whether high MT expression is an independent prognostic factor and increased expression indicates chemotherapy resistance in ovarian cancer, as has been previously suggested, should be determined by further studies.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Endometrioid / chemistry. Cystadenocarcinoma, Serous / chemistry. Cystadenoma, Mucinous / chemistry. Cystadenoma, Serous / chemistry. Metallothionein / analysis. Ovarian Neoplasms / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11860537.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9038-94-2 / Metallothionein
  •  go-up   go-down


16. Schmidt D: [Changes in the endometrium after tamoxifen therapy]. Pathologe; 2006 Feb;27(1):27-32
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes in the endometrium after tamoxifen therapy].
  • [Transliterated title] Endometriumveränderungen nach Tamoxifen-Therapie.
  • Depending on the type of tissue, tamoxifen has either an anti-estrogenic or an estrogenic effect on the cells.
  • In the treatment of breast cancer, the anti-estrogenic effect is used.
  • However, at the same time there is a predominant progestin-like and only mild estrogenic effect on the endometrium.
  • However, endometrial hyperplasia or endometrial carcinoma is identified histologically in only a few cases.
  • In the majority of cases, the diagnosis is endometrial atrophy or endometrial polyp.
  • Other findings related to tamoxifen therapy are stromal decidualisation, regressive hyperplasia, and foci of mucinous, clear cell and serous metaplasia.
  • The main reason for the diagnosis of endometrial hyperplasia on ultrasound could be fibrosis and edema along the border between the endometrium and myometrium.
  • Still unsolved is the question of whether endometrial carcinomas developing after tamoxifen therapy belong mostly to type I (endometrioid) or type II (serous, clear cell) carcinomas.
  • Only in rare cases do malignant neoplasms other than carcinomas develop after tamoxifen therapy.
  • These are adenosarcomas, carcinosarcomas and endometrial stromal sarcomas.
  • [MeSH-minor] Atrophy. Endometrial Neoplasms / chemically induced. Endometrial Neoplasms / pathology. Female. Humans. Polyps / chemically induced. Polyps / pathology. Uterus / drug effects. Uterus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1997 Mar;168(3):657-61 [9057510.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):181-6 [10926800.001]
  • [Cites] Int J Gynecol Cancer. 2000 Jul;10(4):280-284 [11240687.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:179-83 [8747394.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):256-66 [15297160.001]
  • [Cites] Schweiz Med Wochenschr. 1999 Dec 11;129(49):1926-30 [10635085.001]
  • [Cites] Cancer. 2003 Nov 1;98(9):1890-7 [14584071.001]
  • [Cites] Pathologe. 1987 May;8(3):138-40 [3303008.001]
  • [Cites] Arch Gynecol Obstet. 2000 Apr;263(4):170-7 [10834325.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):527-37 [8133536.001]
  • [Cites] Int J Gynecol Pathol. 1995 Jan;14(1):7-15 [7883429.001]
  • [Cites] Cancer Treat Rep. 1985 Feb;69(2):237-8 [3971394.001]
  • [Cites] Obstet Gynecol. 1998 Jan;91(1):40-4 [9464718.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2002 Feb 10;101(1):58-63 [11803101.001]
  • [Cites] Gynecol Oncol. 1998 Aug;70(2):188-91 [9740688.001]
  • [Cites] Lancet. 2000 Sep 9;356(9233):881-7 [11036892.001]
  • [Cites] South Med J. 2003 May;96(5):469-76 [12911186.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3459-63 [11032585.001]
  • [Cites] Hum Pathol. 2003 Sep;34(9):939-43 [14562291.001]
  • (PMID = 16362260.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


17. Kommoss S, Rochon J, Harter P, Heitz F, Grabowski JP, Ewald-Riegler N, Haberstroh M, Neunhoeffer T, Barinoff J, Gomez R, Traut A, du Bois A: Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer. Ann Surg Oncol; 2010 Jan;17(1):279-86
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Treatment of advanced-stage ovarian carcinoma includes radical cytoreductive surgery, which aims at removing all visible tumor tissue followed by platinum and paclitaxel chemotherapy.
  • This paper reports on the prognostic impact of extensive surgery and surgical morbidity in patients with advanced-stage ovarian carcinoma.
  • METHODS: Patients with ovarian carcinoma [Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage IIIB-IV] undergoing primary surgery in our tertiary gynecologic oncology unit between 1997 and 2007 were eligible for this study.
  • Overall survival time was improved in patients who underwent complete tumor resection [hazard ratio (HR) 3.61 (1.91-6.61), P < 0.001].
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898901.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Mundhenke C, Weigel MT, Sturner KH, Roesel F, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Hilpert F, Jonat W, Maass N: Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects. J Cancer Res Clin Oncol; 2008 Dec;134(12):1397-405
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects.
  • METHODS: Expression patterns of abl, c-kit, PDGFR-alpha and PDGFR-beta (Imatinib targets) were studied in 5 cell lines and 111 tissue arrays by PCR and immunohistochemistry.
  • CONCLUSIONS: Our results suggest that Imatinib may be useful for the specific treatment of ovarian cancer as an add-on to conventional chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. Cell Proliferation / drug effects. Ovarian Neoplasms / drug therapy. Receptor, Platelet-Derived Growth Factor alpha / metabolism. Receptor, Platelet-Derived Growth Factor beta / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Benzamides. Carboplatin / administration & dosage. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Female. Humans. Imatinib Mesylate. Immunoenzyme Techniques. Paclitaxel / administration & dosage. Piperazines / administration & dosage. Proto-Oncogene Proteins c-abl / genetics. Proto-Oncogene Proteins c-abl / metabolism. Proto-Oncogene Proteins c-kit / genetics. Proto-Oncogene Proteins c-kit / metabolism. Pyrimidines / administration & dosage. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Tissue Array Analysis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33490-500 [12087097.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3312-22 [11454878.001]
  • [Cites] Biotechniques. 1995 Oct;19(4):640-9 [8777059.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4217-26 [15483033.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):78-86 [15047217.001]
  • [Cites] J Cell Physiol. 1998 Dec;177(3):426-38 [9808151.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S28-36 [12528770.001]
  • [Cites] Endocrinology. 2004 Apr;145(4):2014-22 [14701673.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23432-40 [12697749.001]
  • [Cites] Pathologe. 1987 May;8(3):138-40 [3303008.001]
  • [Cites] Mol Cancer Ther. 2003 Aug;2(8):699-709 [12939459.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):126-31 [16271384.001]
  • [Cites] J Pathol. 2002 Apr;196(4):467-77 [11920744.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3319-26 [10955819.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):385-94 [15617027.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1246-50 [11350890.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10 (2):681-90 [14760091.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):897-908 [14871965.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6271-3; author reply 6273-4 [16135502.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):122-31 [17169414.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1A):407-16 [10769688.001]
  • [Cites] Blood. 2002 Aug 1;100(3):1014-8 [12130516.001]
  • [Cites] Blood. 2001 Apr 1;97(7):1999-2007 [11264164.001]
  • [Cites] Blood. 2001 Feb 15;97(4):1086-91 [11159541.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1087-92 [11861387.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jul-Aug;17(4):784-8 [17343607.001]
  • [Cites] Int J Cancer. 2000 Jun 15;86(6):768-76 [10842189.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1248-59 [11870167.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3084-92 [10963636.001]
  • [Cites] Oncogene. 2006 Mar 30;25(14):2060-9 [16331269.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):2048-55 [15583695.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2929-34 [11306470.001]
  • (PMID = 18465140.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 8A1O1M485B / Imatinib Mesylate; BG3F62OND5 / Carboplatin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; EC 2.7.10.2 / Proto-Oncogene Proteins c-abl; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


19. Timmers PJ, Zwinderman K, Coens C, Vergote I, Trimbos JB: Lymph node sampling and taking of blind biopsies are important elements of the surgical staging of early ovarian cancer. Int J Gynecol Cancer; 2010 Oct;20(7):1142-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The purpose of this study was to determine the effect of lymph node sampling and taking of blind biopsies as part of the surgical staging procedure for early ovarian cancer on disease-free survival (DFS) and overall survival (OS) in patients who received no adjuvant chemotherapy.
  • METHODS: In the EORTC ACTION Trial, 448 patients with early ovarian carcinoma were randomized between November 1990 and March 2000-224 patients to observation and 224 to adjuvant platin-based chemotherapy.
  • The study group did not differ in stage distribution, cell type, or tumor grade.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / surgery. Cystadenocarcinoma, Serous / surgery. Endometrial Neoplasms / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Double-Blind Method. Female. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Single-Blind Method. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21495216.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10 CA11488-20; United States / NCI NIH HHS / CA / 5U10 CA11488-21; United States / NCI NIH HHS / CA / 5U10 CA11488-22; United States / NCI NIH HHS / CA / 5U10 CA11488-23; United States / NCI NIH HHS / CA / 5U10 CA11488-24; United States / NCI NIH HHS / CA / 5U10 CA11488-25; United States / NCI NIH HHS / CA / 5U10 CA11488-26; United States / NCI NIH HHS / CA / 5U10 CA11488-27; United States / NCI NIH HHS / CA / 5U10 CA11488-28; United States / NCI NIH HHS / CA / 5U10 CA11488-29; United States / NCI NIH HHS / CA / 5U10 CA11488-30
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Zhao Y, Wei L: [Umbilical metastasis from malignant neoplasms of pelvic and abdominal cavity with 3 cases analysis]. Zhonghua Fu Chan Ke Za Zhi; 2002 Dec;37(12):736-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the incidence, spreading path, prognosis and treatment of the umbilical metastasis Sister Mary Joseph nodule (SMJN) from malignancies.
  • RESULTS: Three cases SMJN were come from advanced primary peritoneal carcinoma in case 1, recurrent mucinous ovarian papillary adenocarcinoma in case 2 after primary cytoreductive surgery and systemic chemotherapy and case 3 with recurrent endometrial carcinoma.
  • The mean survival was 63 months following surgery or chemotherapy or radiotherapy, case 1 died of advanced malignancy, while case 2 and case 3 were still alive 58 and 44 months, respectively.
  • Umbilical resection should be performed on some patients of SMJN with relative good condition, and chemotherapy or radiotherapy should also performed accordingly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12622918.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


21. Gadducci A, Fuso L, Cosio S, Landoni F, Maggino T, Perotto S, Sartori E, Testa A, Galletto L, Zola P: Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?: A retrospective Italian multicentric study. Int J Gynecol Cancer; 2009 Apr;19(3):367-74
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this retrospective investigation was to assess the pattern of failures of 412 patients with recurrent ovarian cancer followed up with different surveillance protocols.Time to recurrence was less than 6 months in 98 women (23.8%), 6 to 12 months in 102 women (24.7%), and more than 12 months in 212 women (51.5%).
  • Among the 331 asymptomatic patients, the surveillance procedure that raised the suspect of recurrent disease was clinical examination in 49 (14.8%), imaging technique in 90 (27.2%), serum CA 125 in 77 (23.3%), and both serum CA 125 and imaging technique in 115 (34.7%).
  • At univariate analysis, survival from initial diagnosis was related to stage (P = 0.004), residual disease after initial surgery (P < 0.0001), time to recurrence (P < 0.0001), site of relapse (P = 0.04), and treatment at recurrence (P < 0.0001), and survival after recurrence was related to stage (P = 0.01), residual disease (P < 0.0001), time to recurrence (P < 0.0001), and treatment at recurrence (P < 0.0001).
  • Cox proportional hazards model showed that residual disease and time to recurrence were the only independent prognostic variables for both survival from initial diagnosis (P < 0.0001) and survival after recurrence (P < 0.0001).
  • In conclusion, there was no survival difference between asymptomatic and symptomatic patients at the time of relapse, and therefore, the diagnostic anticipation allowed by a scheduled follow-up protocol did not seem to improve the clinical outcome of patients who ultimately developed recurrent disease.
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-125 Antigen / metabolism. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / secondary. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / secondary. Diagnostic Imaging. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / secondary. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Population Surveillance. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407561.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


22. Sufliarsky J, Chovanec J, Svetlovska D, Minarik T, Packan T, Kroslakova D, Lalabova R, Helpianska L, Horvathova D, Sevcik L, Spacek J, Laluha A, Tkacova V, Malec V, Rakicka G, Magdin D, Jancokova I, Dorr A, Stresko M, Habetinek V, Koza I: Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer. Neoplasma; 2009;56(4):291-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
  • Despite progress in primary treatment of patients with advanced ovarian cancer, the majority develop recurrence of the disease.
  • A platinum salt treatment, either as monotherapy or in combination with another cytostatic agent, is indicated for patients who have relapsed 6 or more months after primary treatment and thus have platinum-sensitive relapse.
  • Because repeated use of paclitaxel treatment may lead to substantial neurotoxicity, the combination of gemcitabine with carboplatin represents a suitable treatment option, which is widely used in common clinical practice in the Czech Republic and Slovakia.
  • This non-interventional, prospective study observed the effectiveness and tolerability of second-line treatment with gemcitabine and carboplatin in patients with platinum-sensitive relapse of ovarian cancer in routine clinical practice.
  • The primary endpoint was to evaluate the survival and secondary endpoints were to evaluate time to disease progression, objective tumor response rate, and treatment toxicity.
  • Patients were enrolled to planned second-line treatment with gemcitabine and carboplatin (gemcitabine 1000 mg/m2 and carboplatin AUC 5 on Day 1, and gemcitabine 1000 mg/m2 on Day 8 of a 21-day cycle) for platinum-sensitive relapse of ovarian cancer as a part of routine clinical practice and followed for 12 months.
  • Survival time (using Kaplan-Meier analysis) and objective tumor response rate were calculated using data forms, and a subgroup analysis was performed using log rank tests for time-to-event endpoints; p-values were also calculated.
  • Approximately 91% of patients were originally diagnosed with stage III or IV; 60% of patients had disease free intervals (DFIs) of 12 or more months from previous therapy, and the additional 40% less than 12 months.
  • Median survival time was not determined within the 12-month period following the start of the treatment study due to the limited duration of follow-up.
  • Most common reasons for discontinuation of therapy were "Planned treatment completed" (53%) and "Tumor progression" (11%).
  • Most common toxicities were leukopenia, anaemia, neutropenia, and thrombocytopenia; grades 3 and 4 of these toxicity types did not exceed 30%.
  • Results on time to disease progression are not published due to inconsistent statistical analysis of reported data.
  • Based on this observation from routine clinical practice, which corresponds with previously published results from controlled clinical trials, the gemcitabine and carboplatin combination seems to be a suitable therapeutic option for patients with platinum-sensitive relapse of ovarian cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / secondary. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / secondary. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / secondary. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473054.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


23. Muzii L, Palaia I, Sansone M, Calcagno M, Plotti F, Angioli R, Panici PB: Laparoscopic fertility-sparing staging in unexpected early stage ovarian malignancies. Fertil Steril; 2009 Jun;91(6):2632-7
MedlinePlus Health Information. consumer health - Ovarian Cysts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fertility-sparing staging consisted of exploration of the peritoneal cavity, peritoneal washing cytology, multiple peritoneal biopsies, omolateral adnexectomy (except in borderline tumors), omentectomy, omolateral or bilateral pelvic and aortic lymph node sampling (except in borderline tumors, well differentiated, mucinous, and granulosa cell (GC) neoplasms), endometrial biopsy, appendectomy in mucinous type.
  • Six patients received adjuvant platinum-based chemotherapy.
  • After a median follow-up of 20 months all patients are alive; one patient has FIGO stage Ic clear cell carcinoma, which recurred 8 months after surgery.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18555237.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Fujiwara K, Nagao S, Kigawa J, Noma J, Akamatsu N, Miyagi Y, Numa F, Okada M, Aotani E: Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study. Int J Gynecol Cancer; 2009 Jul;19(5):834-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To assess the antitumor efficacy and safety of 2 treatment modalities: intraperitoneal carboplatin combined with intravenous (IV) paclitaxel.
  • PATIENTS AND METHODS: Eligible patients were those with epithelial ovarian carcinoma or primary peritoneal carcinoma stages II to IV who underwent initial surgery and had a residual tumor size of 2 cm or larger.
  • Large-scale phase III trial comparing with IV carboplatin is warranted in this patient population.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Serous / drug therapy. Endometrial Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Female. Humans. Infusions, Intravenous. Infusions, Parenteral. Maximum Tolerated Dose. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574769.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


25. Tate S, Yamazawa K, Sekiya S: Endometrial cancer within tamoxifen-related polyps in patients with breast cancer. Acta Obstet Gynecol Scand; 2004 Aug;83(8):769-70
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial cancer within tamoxifen-related polyps in patients with breast cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Endometrial Neoplasms / epidemiology. Tamoxifen / adverse effects
  • [MeSH-minor] Adenocarcinoma, Clear Cell / chemically induced. Adenocarcinoma, Clear Cell / epidemiology. Adenocarcinoma, Mucinous / chemically induced. Adenocarcinoma, Mucinous / epidemiology. Adult. Aged. Carcinoma, Endometrioid / chemically induced. Carcinoma, Endometrioid / epidemiology. Female. Humans. Japan / epidemiology. Medical Records. Middle Aged. Polyps / chemically induced. Polyps / epidemiology. Retrospective Studies

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15255851.001).
  • [ISSN] 0001-6349
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down






Advertisement